Spodoptera frugiperda, Sf 21 (baculovirus)-derived human F13A1 protein Ser2-Met732 with an N-terminal Met and 6-His tag
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
<0.10 EU per 1 μg of the protein by the LAL method.
N-terminal sequence Analysis
No results obtained, Met predicted. Protein identity confirmed by MS analysis of tryptic fragments.
Predicted Molecular Mass
76-88 kDa, under reducing conditions
Measured by its ability to release DNP from Abz-NE(CAD-DNP)EQVSPLTLLK-OH. The specific activity is >13.0 pmol/min/μg, as measured under the described conditions.
Recombinant Human F13A1 His-tag Protein, CF Scientific Data Examples
Recombinant Human F13A1 His-tag Protein Enzyme Activity
Recombinant Human F13A1 His-tag (Catalog # 10179-F1) is measured by its ability to release DNP from Abz-NE(CAD-DNP)EQVSPLTLLK-OH. The activity (orange) is approximately 2-fold higher than the competitor's F13A1 (green).
Recombinant Human F13A1 His-tag Protein SDS-PAGE
2 μg/lane of Recombinant Human F13A1 His-tag was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® blue staining, showing a band at ~82 kDa under reducing conditions.
Formulation, Preparation and Storage
What does CF mean?
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our
Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant
protein to be stored at a more dilute concentration.
The carrier free version does not contain BSA.
What formulation is right for me?
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or
as an ELISA standard.
In contrast, the carrier free protein is recommended for applications, in which the presence of BSA
Supplied as a 0.2 μm filtered solution in Tris, NaCl, EDTA, Glycerol and TCEP.
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
6 months from date of receipt, -70 °C as supplied.
3 months, -70 °C under sterile conditions after opening.
Coagulation Factor XIIIa1 (F13a1) is a member of the transglutaminase family which includes F13A1 and TGM1-7 (1). F13 in the plasma is a tetrameric complex composed of two alpha (A) and two beta (B) chains where the A subunit is a transglutaminase zymogen and the B subunit is an inhibitory glycoprotein with no enzymatic function (2). Activation by thrombin and calcium ions results in the formation of the catalytically active transglutaminase F13a composed of an alpha chain homodimer capable of forming gamma-glutamyl-epsilon-lysine cross-links. The 83 kDa F13a monomer has an N-terminal activation peptide and a beta sandwich preceding the catalytic core with catalytic triad active site and two C-terminal beta barrels (3). The active homodimer is intracellular in platelets, megakaryocytes, monocytes and macrophages. The primary physiological outcome of the catalytic activity of F13a is cross-linking of fibrin and anti-plasmin to stabilize the fibrin clot (4,5). However, in addition to cross-linking fibrin, F13a is capable of cross-linking many substrates involved in complement activation, coagulation, inflammatory and immune responses and extracellular matrix organization (6). Cross-linking of key substrates by F13a has been directly shown to play a role in in atherosclerosis (7), wound healing (8), angiogenesis (9,10), maintaining pregnancy (11), ECM deposition, osteoblast differentiation and bone remodeling (12), and immune defense (13). F13A has also been detected as a marker in acute promyelocytic leukemia (APL)(14) and expression is considered of value for diagnosis and prognosis for leukemia-associated immunophenotype. Congenital deficiency results in bleeding manifestations including intercranial hemorrhage (15), poor wound healing (17), and spontaneous abortions (17) that can be treated with F13 (18).
Griffin, M. et al. (2002) Biochem. J. 368:377.
Muszbek, L. et al. (1999) Thromb. Res. 94:271.
Yee, V. C. et al. (1994) Proc. Natl. Acad. Sci. USA 91:7296.
Lord, S. T. et al. (2011) Aterioscler. Thromb. Vasc. Biol. 31:494.
Fraser, S. R. et al. (2011) Blood 117:6371.
Nikolajsen, C. L. et al. (2014) J. Biol. Chem. 289:6526.
AbdAlla, S. et al. (2004) Cell. 119:343.
Nahrendorf, M. et al. (2006) Circulation 113:1196.
Dardik, R. et al. (2006) Thromb. Haemost. 95:546.
Dardik, R. et al. (2005) Arterioscler. Thromb. Vasc. Biol. 25:526
Asahina, T. et al. (2000) Placenta. 21:388.
Piercy-Kotb, S. A. et al. (2012) J. Cell Physiol. 227:2936.
Richardson, V. R. et al. (2012) Br. J. Haematol. 160:116.
Simon, A. et al. (2012) Cytometry B. Clin. Cytom. 82:209.
Naderi, M. et al. (2015) Hematology. 20:112.
Inbal, A. et al. (2005) Thromb. Haemost. 94:432.
Inbal, A. and L. Muszbek. (2003) Semin. Thromb. Hemost. 29:171
Naderi, M. et al. (2016) Iran J. Pharm. Res. 15:635.
Coagulation Factor XIII, A1 Polypeptide
Entrez Gene IDs
Coagulation factor XIIIa, EC 184.108.40.206, F13A, F13A1, F13Acoagulation factor XIII, A polypeptide, FSF, A Subunit, Protein-glutamine gamma-glutamyltransferase A chain, TGase, Transglutaminase A chain, bA525O21.1 (coagulation factor XIII, A1 polypeptide), coagulation factor XIII A chain, coagulation factor XIII, A1 polypeptide, factor XIIIa, fibrin stabilizing factor, A subunit, fibrinoligase, transglutaminase. plasma
Citations for Recombinant Human F13A1 His-tag Protein, CF
Which Brands are Currently Available on bio‑techne.com? R&D Systems, Tocris Bioscience and ProteinSimple branded products are available to purchase through bio‑techne.com. ProteinSimple branded instruments are available to quote. ACD branded products will be available on bio‑techne.com in the near future. Novus Biologicals branded products are not currently available on bio‑techne.com and can be found at novusbio.com.
Setting the standard in quality research reagents for over 30 years
A trusted leader in quality life science reagents
Your trusted supplier for innovative and high performance life science reagents
Proprietary systems and consumables for simpler, more quantitative and affordable protein analysis
Proprietary RNAscope® technology capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity
A world leader in developing liquid biopsy based diagnostics